Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of 601 Versus Ranibizumab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Next Previous
Trial Profile

A Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of 601 Versus Ranibizumab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 601 A (Primary) ; Ranibizumab
  • Indications Branch retinal vein occlusion; Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms BRVO
  • Sponsors Sunshine Guojian Pharmaceutical

Most Recent Events

  • 18 Dec 2025 Actual primary completion date is 23 Sep 2024.
  • 18 Dec 2025 Status changed from recruiting to completed.
  • 11 Jan 2023 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top